Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-74699157 · 1 trial · 4 indications
DLTs are defined as certain non-hematologic and hematologic toxicities of Grade 3 or higher.
An AE is any untoward medical occurrence in a participant who received study drug without regard to causal relationship.
Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life threatening consequences; Grade 5: Death.
ORR is defined as the percentage of participants who have a partial response (PR) or better response as per RECIST v.1.1. PR criteria in solid tumors (RECIST) is greater than or equal to (\>=) 30 percent (%) decrease in the sum of the diameters of all index lesions compared with baseline in 2 observations at least 4 weeks apart, in absence of new lesions or unequivocal progression of non-index lesions.
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation | EXPERIMENTAL | Participants with advanced solid tumors harboring the kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation will receive oral administration of JNJ-74699157. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET) until the recommended Phase 2 Dose (RP2D) has been identified. |
| Part 2: Dose Expansion | EXPERIMENTAL | Two groups of participants with either non-small cell lung cancer or other solid tumors harboring KRAS G12C mutation will receive JNJ-74699157 at RP2D determined in Part 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-74699157 | DRUG | Participants will receive JNJ-74699157 orally. |
Inclusion Criteria: * Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumor tissue or blood * Histological documentation of disease: Part 1: Histologically or cytologically confirmed solid tumor malignancy that is metastatic or unresectable, Part 2: (a) unresectable,...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
JNJ-74699157 is an investigational small molecule being studied for the treatment of neoplasms, including advanced solid tumors, non-small cell lung cancer, and colorectal cancer. It is being developed for patients whose tumors harbor the KRAS G12C mutation. The drug is currently in Phase 1 clinical development.
JNJ-74699157 targets tumors that harbor the KRAS G12C mutation. It is designed to act on cancers with this specific genetic alteration. The drug is being evaluated in patients with advanced solid tumors, non-small cell lung cancer, and colorectal cancer that carry the KRAS G12C mutation.
JNJ-74699157 is being developed by Johnson & Johnson, a company traded on the stock exchange under the ticker JNJ. The drug is an investigational small molecule in Phase 1 clinical development for the treatment of neoplasms, including advanced solid tumors, non-small cell lung cancer, and colorectal cancer.
JNJ-74699157 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is being studied in a first-in-human trial for patients with tumors harboring the KRAS G12C mutation, including advanced solid tumors, non-small cell lung cancer, and colorectal cancer.
JNJ-74699157 is being studied in a Phase 1 clinical trial with the identifier NCT04006301. This first-in-human study enrolled 10 participants with tumors harboring the KRAS G12C mutation, including advanced solid tumors, non-small cell lung cancer, and colorectal cancer. The trial was conducted in the United States and France and has been completed.
JNJ-74699157 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied for the treatment of neoplasms, including advanced solid tumors, non-small cell lung cancer, and colorectal cancer, in patients with tumors harboring the KRAS G12C mutation.